Omega-3, Omega-6, and Polyunsaturated Fat for Cognition: Systematic Review and Meta-analysis of Randomized Trials.

This systematic review and meta-analysis investigated the effects of increasing intake of various types of polyunsaturated fats (PUFAs) on cognitive function. The specific interventions tested in the included studies were:

**Long-chain omega-3 fatty acids (LCn3):** These include eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), typically found in oily fish and supplements. Doses ranged from 150 mg/day to 4.4 g/day, with most trials using 400-2400 mg/day.

**Alpha-linolenic acid (ALA):** A plant-based omega-3 fatty acid found in flaxseed, chia seeds, and walnuts.

**Omega-6 fatty acids:** Such as linoleic acid, found in vegetable oils.

**Total polyunsaturated fatty acids (PUFA):** The combined intake of all polyunsaturated fats.

These interventions were compared against **lower intake** of these fats, which typically meant a **usual diet, no advice, no supplementation, or a placebo** (e.g., an inert capsule or a control food).

The primary outcomes measured across the included studies, and then synthesized in this review, were:

**New neurocognitive illness:** The incidence of conditions like dementia.

**Newly impaired cognition:** The development of measurable cognitive decline.

**Continuous measures of cognition:** These were grouped into domains including:

* **Global cognition:** Overall mental function.

* **Executive function:** Planning, problem-solving, working memory.

* **Processing speed:** How quickly mental tasks are performed.

* **Memory:** Including verbal, spatial, and other forms of memory, as well as attention.

The meta-analysis included data from **38 randomized controlled trials (RCTs)**, which comprised **41 distinct comparisons** and a total of **49,757 adult participants**.

**Population:** Participants were adults aged 18 years or older. They included individuals with **normal cognitive function** at baseline (for primary prevention studies) as well as those already diagnosed with **cognitive impairment or neurocognitive illness** (for secondary prevention studies). Pregnant or seriously ill individuals were excluded from the original trials.

**Setting:** The vast majority of the included trials (36 out of 38) were conducted in **high-income countries**.

**Duration:** The minimum duration for trials to be included was **24 weeks (6 months)**, with the average duration of the included trials being **21 months**. This longer duration was chosen to allow sufficient time for metabolic changes and potential cognitive effects to manifest.

The individual trials included in the meta-analysis used a wide variety of instruments and scales to measure cognitive function. To synthesize these diverse measures, the reviewers standardized the approach:

**Grouping of Measures:** Neurocognitive measures were grouped into established domains such as global cognition, executive function, processing speed, and memory. This was done by researching the derivation, purpose, and interpretation of each specific metric used in the individual studies.

**Standardization of Scales:** The direction of all scales was standardized so that a lower score consistently indicated lower levels of cognitive ability.

**Meta-analytic Combination:** Different scales within the same cognitive domain were combined using **standardized mean differences (SMD)**. This statistical technique allows for the pooling of results from studies that used different measurement tools but assessed the same underlying construct.

**Preference for Specific Tests:** When a single study reported multiple tests within a domain, the results from the "best, most commonly used, and most immediate" tests were prioritized for inclusion in the meta-analysis to ensure the most useful data was utilized.

**Specific Example:** For global cognition, the **Mini-Mental State Examination (MMSE)** was one of the commonly used instruments, with the meta-analysis reporting a mean difference for this specific scale. The MMSE is a 30-point questionnaire used to assess cognitive impairment, with higher scores indicating better cognitive function.

This study is a **systematic review and meta-analysis of randomized controlled trials (RCTs)**. This design is considered the highest level of evidence for assessing the effectiveness of interventions.

**How they ran the study:**

1. **Search Strategy:** The researchers conducted extensive searches across major medical and trials databases including Medline, Embase, Cochrane CENTRAL, ClinicalTrials.com, and the World Health Organization International Clinical Trials Registry Platform. The final update for ongoing trials was in December 2018. They also checked references of relevant systematic reviews and contacted authors for additional data, including unpublished summaries.

2. **Inclusion Criteria for RCTs:**

* **Participants:** Adults (18+ years), not pregnant or seriously ill, with or without existing neurocognitive illness or impairment.

* **Intervention:** Comparison of higher versus lower intake of omega-3, omega-6, and/or total PUFA. Interventions could be foodstuffs, oral supplements (oil, capsules), or dietary advice. A change of at least 10% from baseline intake was required if no specific aim was stated.

* **Comparator:** Usual diet, no advice, no supplementation, or placebo.

* **Exclusions:** Trials involving multiple risk factor interventions (e.g., diet *and* exercise) were excluded to isolate the effect of PUFAs.

* **Duration:** A minimum duration of **24 weeks (6 months)** was required. This duration was chosen because metabolic studies suggest 6 months is the minimum time needed for long-chain omega-3s to equilibrate in most body compartments, including the brain.

* **Outcomes:** Studies were included if they collected data on any of the primary outcomes (new neurocognitive illness, newly impaired cognition, global cognition, executive function,